Auto Amazon Links: No products found.
The United Kingdom has commenced human trials of a newly developed Ebola vaccine following approval from the national regulatory authority. This vaccine, created by researchers at the University of Oxford, was rapidly developed within just eight weeks after a public health emergency was declared on May 17. It is the first of four candidate vaccines targeting the Bundibugyo species of Ebola to reach clinical testing. Recruitment of volunteers is underway, with initial doses expected to be administered to healthy adults in the UK within a few weeks.
The ongoing Ebola epidemic, primarily affecting the Democratic Republic of the Congo, has resulted in 625 fatalities alongside 1,792 laboratory-confirmed cases. The outbreak is caused by the Bundibugyo strain, which has been responsible for two prior outbreaks. Ebola is categorized into six distinct species that require different medical approaches; hence, no currently approved vaccines or drugs are available for the Bundibugyo variant. The epidemic continues to spread in a conflict-affected area with a highly mobile population, highlighting the urgent necessity of an effective vaccine.
Leading the clinical trial efforts, Dr. Katrina Pollock of the University of Oxford explained that phase one trials, which involve early-stage testing, occur regularly to prepare for outbreaks such as this. The trial will include 50 healthy adults aged between 18 and 55, with collaborations established in Uganda to facilitate trials in Africa. Participants will be monitored over the course of a year to assess immune responses and identify any adverse effects. The rapid development of the vaccine was made possible by leveraging the same technology that underpinned the Oxford/AstraZeneca COVID-19 vaccine.
This vaccine uses a genetically modified chimpanzee adenovirus, which is harmless to humans, to deliver a small fragment of genetic material from the Ebola virus into the body. Unlike a live virus, this snippet triggers the production of a single viral protein that prompts the immune system to recognize and respond to Ebola. Consequently, the body can mount a defense if exposed to the virus in the future. Before entering human trials, the vaccine underwent testing in mice and macaque monkeys and is being produced to clinical standards by the Serum Institute of India, which has already stockpiled approximately 620,000 doses. Alex Sampson, one of the vaccine researchers, emphasized that the rapid scaling of production was enabled by the immediate response to the outbreak, while assuring that all standard safety and efficacy tests are being conducted without shortcuts
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.